Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (11-20 of 518) with videos related to

Pageof 52
Sort By:
The Lancet. Haematology|December 3, 2017
Serum protein markers of clonal heterogeneity in myelomaOla Landgren
Blood|February 21, 2009
A role for ionizing radiation in myelomagenesis?Ola Landgren
Seminars in Oncology|January 8, 2017
Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk statusOla Landgren
Hematology. American Society of Hematology. Education Program|December 10, 2021
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic eventsOla Landgren
Seminars in Hematology|May 14, 2026
Minimal residual disease testing in hematologic malignancies: From early endpoint to precision clinical decision makingOla Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Multiple myeloma: Current advances and future directionsC Ola Landgren
JAMA Oncology|July 21, 2022
Novel Quadruplets and the Age of Immunotherapies in the Treatment of Newly Diagnosed Multiple MyelomaDickran Kazandjian, Ola Landgren
Lancet (London, England)|August 13, 2021
A new era of novel immunotherapies for multiple myelomaDickran Kazandjian, Ola Landgren
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2022
Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!Ola Landgren, Dickran Kazandjian
Leukemia & Lymphoma|October 15, 2008
Epidemiology, pathology and treatment of non-follicular indolent lymphomasOla Landgren, Hervé Tilly
Pageof 52

Showing results (11-20 of 518) with videos related to

Sort By:
Pageof 52
The Lancet. Haematology|December 3, 2017
Serum protein markers of clonal heterogeneity in myelomaOla Landgren
Blood|February 21, 2009
A role for ionizing radiation in myelomagenesis?Ola Landgren
Seminars in Oncology|January 8, 2017
Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk statusOla Landgren
Hematology. American Society of Hematology. Education Program|December 10, 2021
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic eventsOla Landgren
Seminars in Hematology|May 14, 2026
Minimal residual disease testing in hematologic malignancies: From early endpoint to precision clinical decision makingOla Landgren
Best Practice & Research. Clinical Haematology|March 7, 2020
Multiple myeloma: Current advances and future directionsC Ola Landgren
JAMA Oncology|July 21, 2022
Novel Quadruplets and the Age of Immunotherapies in the Treatment of Newly Diagnosed Multiple MyelomaDickran Kazandjian, Ola Landgren
Lancet (London, England)|August 13, 2021
A new era of novel immunotherapies for multiple myelomaDickran Kazandjian, Ola Landgren
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2022
Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!Ola Landgren, Dickran Kazandjian
Leukemia & Lymphoma|October 15, 2008
Epidemiology, pathology and treatment of non-follicular indolent lymphomasOla Landgren, Hervé Tilly
Pageof 52